title: Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting.
abstract: Weight gain is a frequently occurring serious somatic adverse effect of atypical antipsychotic agents. Genetic factors influence the risk of an individual to gain weight.
  
  
  OBJECTIVE
  To determine whether LEPR Q223R, LEP -2548G/A and HTR2C -759C/T polymorphisms are associated with obesity and weight change in patients using atypical antipsychotic drugs.
  
  
  METHODS
  A longitudinal study design was used in a naturalistic setting. The study population included 141 patients, all of whom were using an atypical antipsychotic drug. The body mass index was measured twice. Primary outcome measures were obesity at the moment of first measurement and body mass index change during treatment. Determinants were the LEPR Q223R (rs1137101), the LEP -2548G/A SNP (rs7799039) and the HTR2C -759C/T (rs3813929) polymorphisms.
  
  
  RESULTS
  Of the 141 included patients, 35 (24.8%) were obese. In females, presence of the LEPR 223R allele was associated with an increased risk of obesity (47.6 vs 17.6%; p = 0.03). In males this association was not found. None of the SNPs were significantly associated with weight change during treatment.
  
  
  CONCLUSIONS
  The LEPR Q223R polymorphism may be a risk factor for obesity in women with a psychotic disorder treated with atypical antipsychotic drugs. This is in line with earlier findings of our group.
authors.affiliation: Psychiatric Hospital Meerkanten, Ermelo, The Netherlands.
authors.forename: Jochem G
authors.initials: JG
authors.lastname: Gregoor
authors.forename: Jan
authors.initials: J
authors.lastname: van der Weide
authors.forename: Harriët M
authors.initials: HM
authors.lastname: Loovers
authors.forename: Harold J G M
authors.initials: HJ
authors.lastname: van Megen
authors.forename: Toine C G
authors.initials: TC
authors.lastname: Egberts
authors.forename: Eibert R
authors.initials: ER
authors.lastname: Heerdink
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D020738:Leptin / Q000235:genetics*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011618:Psychotic Disorders / Q000188:drug therapy / Q000235:genetics; D044405:Receptor, Serotonin, 5-HT2C / Q000235:genetics*; D054411:Receptors, Leptin / Q000235:genetics*; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; C515448:LEPR protein, human; D020738:Leptin; D044405:Receptor, Serotonin, 5-HT2C; D054411:Receptors, Leptin